UNSPSC 51281673: Streptomycin b

This classification denotes an aminoglycoside antibiotic with the molecular formula C27H49N7O17, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CJ1467C885, chemically known as d-streptamine, o-.beta.-d-mannopyranosyl-(1->4)-o-2-deoxy-2-(methylamino)-.alpha.-l-glucopyranosyl-(1->2)-o-5-deoxy-3-c-formyl-.alpha.-l-lyxofuranosyl-(1->4)-n1,n3-bis(aminoiminomethyl)-, but more generally known as streptomycin b, which bears US NIH Compound Identifier 121307.

UNSPSC 51281673 Streptomycin B, a Commodity code, shows limited recent activity directly aligned with the code's pharmaceutical scope. The recent solicitations tagged under this code actually pursue naloxone and drug deactivation systems, medical and first aid supplies for emergency response, generic multi-source pharmaceuticals and OTC products through cooperative purchasing, and direct-to-manufacturer pharmacy programs — a mix that reflects state and local health and human services procurement activity but does not center on streptomycin specifically. State and local issuing bodies pursuing pharmaceutical and medical supply contracts include county health departments, city fire departments, state health commissions, and cooperative purchasing alliances serving multiple jurisdictions. The work spans product supply, distribution logistics, compliance with cGMP and DSCSA standards, insurance and bonding requirements, and eligibility verification (E-Verify, drug-free workplace certification).

Recent opportunities span Florida, Texas, Minnesota with multi-state reach, and the broader Midwest through cooperative vehicles. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly delivery and a response deadline of July 26, 2023. The City of Tampa issued ITB 26P00145 in March 2026 for medical and first aid supplies (169 line items) for the Fire Department Rescue Division, with a $700,000 estimated contract value and a sheltered-market set-aside for certified Small Local Business Enterprises; the response deadline was March 13, 2026. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products, with a proposal due date of March 26, 2026 and contract effectiveness July 1, 2026, distributing through authorized wholesalers nationwide. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather market intelligence on direct-to-manufacturer pharmacy programs; this exploratory phase does not include formal evaluation criteria or award amounts.